Closed · RFA-DK-27-146 · CFDA 93.847 · Discretionary
New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $500K
- Award range
- Closed
- Status
- June 17, 2026
- Close date
- 5
- Expected awards
The verdict
New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $500,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number.
- up to $500K
- award range
- Closed
- application status
- 5
- expected awards
- 93.847
- CFDA program
Opportunity snapshot. This Grants.gov announcement - New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional) - is cataloged under number RFA-DK-27-146 and tied to CFDA assistance listing 93.847, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on May 7, 2026. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $500,000. The agency has projected $3.0 million in total estimated funding for this announcement. It expects to issue 5 awards. If the agency funds the expected 5 awards from the $3.0 million estimated pool, the average award works out to roughly $600,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on June 17, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $500,000
Close Date
June 17, 2026
Posted
May 7, 2026
Est. Total Funding
$3,000,000
Expected Awards
5
Instrument
Grant
Description
The purpose of this funding opportunity is to support research addressing barriers that limit progress toward more effective open- and closed-loop diabetes control systems. This may include research that addresses: 1) innovation of sensing relevant analytes/physiologic signals; 2) novel formulation and delivery of hormones; 3) artificial intelligence (AI)/machine learning (ML)-driven tools/algorithms; and 4) digital twin modeling to augment decision support and automated control systems with the goal of improving glycemic control, reducing burden of care, and enhancing quality of life of people with T1D].This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Diabetes, Endocrine, and Metabolic Disease Research
National Institutes of Health
Agency Contact
Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK_DEM@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |